Department of Neurology, Sahlgrenska Academy at University of Gothenburg, Sweden.
Mult Scler. 2013 Jun;19(7):871-6. doi: 10.1177/1352458512463766. Epub 2012 Oct 4.
Recently, a polymorphism in the LIGHT gene was shown to increase the risk of multiple sclerosis (MS) in a genome-wide association study (GWAS).
Our aim was to investigate if serum levels of LIGHT were affected by this polymorphism and by the disease itself.
Serum levels of LIGHT were investigated in four cohorts; 1) MS (n = 159) and controls (n = 160) in relation to rs1077667 genotype; 2) MS at relapse (n = 30) vs. healthy controls (n = 26); 3) MS (n = 27) vs. other neurological disease (OND, n = 33); and 4) MS patients before and after one year of treatment with natalizumab (n = 30).
Carriers of the GG genotype had the lowest serum levels of LIGHT (p=0.02). Serum levels of LIGHT were increased in MS at relapse in two separate cohorts: vs. healthy controls (p=0.00005) and vs. remission (p=0.00006), other neurological disease (OND) (p=0.002) and OND with signs of inflammation (iOND; p=0.00005). Furthermore, serum levels of LIGHT were decreased by natalizumab treatment (p=0.001).
Soluble LIGHT is an inhibitor of T-cell activation and GG carriers of rs1077667, with the highest risk for MS, had the lowest serum levels. The increased levels of LIGHT at times of increased MS activity suggest that soluble LIGHT is protective and may act to limit inflammation.
最近，一项全基因组关联研究（GWAS）表明，LIGHT 基因的一种多态性增加了多发性硬化症（MS）的风险。
我们旨在研究这种多态性以及疾病本身是否会影响 LIGHT 的血清水平。
我们研究了四个队列的 LIGHT 血清水平；1）MS（n = 159）和对照组（n = 160）与 rs1077667 基因型的关系；2）MS 复发时（n = 30）与健康对照组（n = 26）；3）MS（n = 27）与其他神经系统疾病（OND，n = 33）；4）接受那他珠单抗治疗前后的 MS 患者（n = 30）。
GG 基因型携带者的 LIGHT 血清水平最低（p=0.02）。在两个独立的队列中，MS 复发时 LIGHT 血清水平升高：与健康对照组（p=0.00005）和缓解期（p=0.00006）、其他神经系统疾病（OND）（p=0.002）和有炎症迹象的 OND（iOND；p=0.00005）。此外，LIGHT 血清水平在那他珠单抗治疗后降低（p=0.001）。
可溶性 LIGHT 是 T 细胞激活的抑制剂，rs1077667 的 GG 携带者患 MS 的风险最高，其血清水平最低。MS 活动增加时 LIGHT 水平升高表明，可溶性 LIGHT 具有保护作用，可能作用于限制炎症。
